A Phase 2 interventional study of Dalcetrapib and Placebo in Covid19, sponsored by DalCor Pharmaceuticals. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-07.
Sponsored by DalCor Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 289 studies in COVID-19 with a site in Canada — 24 open to participants now, 36 under way, 8 of them phase 3. COVID-19 · Canada.
Among the 289 studies in COVID-19 with a site in Canada, this one is the 79th largest by enrollment of the 200 interventional ones that give a count, is one of 95 that started in 2021, is one of 28 in phase 2, and was the 134th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →24 of the 289 studies in COVID-19 with a site in Canada are open now. Recruiting first, the newest first:
University of British Columbia · Sites in Canada
Healthy volunteers
ParagonClinicals Inc. · Sites in Canada
Ages 19+
Unity Health Toronto · Sites in Canada
Ages 18+
Douglas D. Fraser · Sites in Canada, United States, Brazil and 4 more countries
Ages 18–65
McMaster University · Sites in Canada
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
289 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 51 · Phase 3 55 · Phase 4 6
First in 2014; this study’s year is marked. 95 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 227 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 120 across the 200 interventional studies, 355 across the 88 observational. Of the 196 that completed or were terminated, 36 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 289 have an industry lead sponsor. The 10 most frequent:
DalCor Pharmaceuticals is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
DalCor Pharmaceuticals has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
12 of the studies in COVID-19 with a site in Canada that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07314905Phase 3Unity Health TorontoAdaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) | 2027-03-31 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
Add all 12 to your calendar (.ics) → With an account.
Among the 289 studies in COVID-19 with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a placebo-controlled, Phase 2a proof-of-concept clinical study which will evaluate efficacy and safety of dalcetrapib in outpatients patients with mild to moderate, symptomatic, confirmed COVID 19.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must satisfy all of the following criteria unless otherwise stated:
Have mild to moderate signs or symptoms of COVID-19 with onset within 5 days of first dose on Day 1, at least two of the following symptoms:
Exclusion Criteria:
Patients will be excluded from the study if they satisfy any of the following criteria unless otherwise stated:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive Dalcetrapib 900 mg for 10 days
Drug: Dalcetrapib
Patients will receive Dalcetrapib 1800 mg for 10 days
Drug: Dalcetrapib
Patients will receive Dalcetrapib 3600 mg for 10 days
Drug: Dalcetrapib
Patients will receive Placebo for 10 days
Other: Placebo
Dalcetrapib 300 mg Film-Coated Tablets
Placebo Tablets
Time to Sustained Clinical Resolution of Symptoms of COVID-19 (Excluding Cough, Sense of Smell and Taste) in Subjects With Confirmed, Mild to Moderate, Symptomatic COVID-19 Treatment With Dalcetrapib
Sustained clinical resolution is defined as occurring when no key COVID-19 related symptom has a score higher than 1 over a 72-hour period (as documented using an electronic patient-reported outcome \[ePRO\] instrument), except for sense of smell and taste where the score should be 0 over a 72-hour period. The time to resolution was taken as the time from randomization until the first day of the last 72-hour period where the patient met the definition of resolution within 28 days. Patients who did not meet the definition of resolution 28 days after randomization were considered not resolved. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" from the Food and Drug Administration (FDA). The symptoms are scored as on a scale of 0 to 3 for 12 of the symptoms where 0 is none and on a scale of 0 to 2 for the two other symptoms where 0 is "as usual". A higher score is a worse outcome.
Time frame: 28 days
Change From Baseline in log10 Viral Load (Saliva)
Log10 viral load, as assessed using the saliva, was summarized by treatment group using descriptive statistics (N, mean, median, standard deviation, minimum, and maximum) for each visit as well as for changes from baseline where an 80% CI were also presented. A repeated ANCOVA model was used for the data shown below, showing the mean changes from baseline to study visits (Day 3, Day 5, Day 10, and Day 28/EOS) in log10 viral load including treatment groups by study visit interaction, baseline value of log10 viral load and baseline value of log10 viral load by study visit interaction.
Time frame: Screening/Baseline (Day -2 to Day -1), Day 3, Day 5, Day 10, and Day 28/End of Study (EOS)
Change From Baseline in log10 Viral Load (Nasal Swab)
Log10 viral load, as assessed using the nasal swab, was summarized by treatment group using descriptive statistics (N, mean, median, standard deviation, minimum, and maximum) for each visit as well as for changes from baseline where an 80% CI were also presented. A repeated ANCOVA model was used for the data shown below, showing the mean changes from baseline to study visits (Day 3, Day 5, Day 10, and Day 28/EOS) in log10 viral load including treatment groups by study visit interaction, baseline value of log10 viral load and baseline value of log10 viral load by study visit interaction.
Time frame: Screening/Baseline (Day -2 to Day -1), Day 3, Day 5, Day 10, and Day 28/End of Study (EOS)
Time to Sustained Complete Clinical Resolution of Symptoms in Subjects With Confirmed, Mild to Moderate, Symptomatic COVID-19 Treatment With Dalcetrapib
Sustained clinical resolution is defined as occurring when no key COVID-19 related symptom has a score higher than 1 over a 72-hour period (as documented using an electronic patient-reported outcome \[ePRO\] instrument). The time to resolution was taken as the time from randomization until the first day of the last 72-hour period where the patient met the definition of resolution within 28 days. Patients who did not meet the definition of resolution 28 days after randomization were considered not resolved. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" from the Food and Drug Administration (FDA). The symptoms are scored as on a scale of 0 to 3 for 12 of the symptoms where 0 is none and on a scale of 0 to 2 for the two other symptoms where 0 is "as usual". A higher score is a worse outcome.
Time frame: 28 days
Viral Clearance Using Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) Polymerase Chain Reaction (PCR)
Viral clearance based on polymerase chain reaction (PCR) test for Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) using nasal swab and saliva samples was performed on the intention-to-treat (ITT) population. Viral clearance was summarized by treatment group using Kaplan-Meier methods. Median and associated 80% confidence interval (CI) was presented. The number and percentage of patients who did not show viral clearance, did show viral clearance, and patients censored were presented.
Time frame: Day 1 to Day 28
Time to Complete Clinical Resolution (Excluding Cough, Sense of Smell and Taste) Defined in the Same Way as the Primary Endpoint, But Considering That All Symptoms Must Resolve to a Score of 0 for 72 Hours
Complete clinical resolution is defined as occurring when no key COVID-19 related symptom (excluding cough, sense of smell and taste) has a score higher than 0 over a 72-hour period. The time to resolution was taken as the time from randomization until the first day of the last 72 hour period where the patient met the definition of resolution within 28 days. Patients who did not meet the definition of resolution 28 days after randomization were considered not resolved. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" was used. The symptoms are scored as on a scale of 0 to 3 for 12 of the symptoms where 0 is none and on a scale of 0 to 2 for the two other symptoms where 0 is "as usual". A higher score is a worse outcome.
Time frame: 28 days
Time to Complete Clinical Resolution
Sustained clinical resolution is defined as occurring when no key COVID-19 related symptom has a score higher than 0 over a 72-hour period. The time to resolution was taken as the time from randomization until the first day of the last 72 hour period where the patient met the definition of resolution within 28 days. Patients who did not meet the definition of resolution 28 days after randomization were considered not resolved. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" was used. The symptoms are scored as on a scale of 0 to 3 for 12 of the symptoms where 0 is none and on a scale of 0 to 2 for the two other symptoms where 0 is "as usual". A higher score is a worse outcome. Resolution must have occurred within 28 days. Time of resolution of 29 days was imputed in censored subjects.
Time frame: 28 days
Change From Baseline in Coronavirus Disease of 2019 (COVID-19) Total Symptom Severity Score Collected at All Time Points
COVID-19 total symptom severity score was summarized by treatment group using descriptive statistics (N, mean, median, standard deviation, minimum, and maximum) for each visit as well as for changes from baseline where an 80% confidence interval (CI) was also presented. Mean changes from baseline were analyzed using a repeated measures ANCOVA model. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" from the Food and Drug Administration (FDA) document "Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment Guidance for Industry". Symptoms are scored as on a scale of 0 to 3 for 12 the symptoms and on a scale of 0 to 2 for two symptoms. The sum of all 14 symptom scores is reported, where 0 is the minimum and 40 is the maximum. A higher score is a worse outcome.
Time frame: Baseline, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 14 (follow-up visit 1), and Day 28 (end of study / follow-up visit 2)
Scoring of World Health Organization (WHO) Clinical Outcome Scale (9-point Scale) at Screening, Days 1, 3, 5, End of Treatment (Day 10), Follow-Up Visit (Day 14), and Day 28
The number and percentage of patients for each WHO clinical outcome score was summarized. Scores were compared using the Mann-Whitney-Wilcoxon test. This scale is called the "WHO Clinical Outcome Scale". It is scored from 0 to 9 where 9 is the most severe disease presentation. A higher score is a worse outcome.
Time frame: Screening (Day -2 to Day -1), Days 1, 3, 5, End of Treatment (Day 10), Follow-Up Visit (Day 14), and Day 28
Rate of Hospitalization Through Day 28
The analysis of this endpoint was performed on the intention-to-treat (ITT) population. The percentage of patients who were hospitalized was compared using a binary logistic regression analysis. The model included only the treatment group. The results were presented as odds ratios, with associated 80% CIs and p-value.
Time frame: Day 1 to Day 28
Rate of Progression to Oxygen Therapy Through Day 28
The analysis of this endpoint was performed on the intention-to-treat (ITT) population. The number and percentage of patients who progressed to oxygen therapy was presented. The percentage of patients who had progressed to oxygen therapy was compared using a binary logistic regression analysis. The model included only the treatment group. The results were presented as odds ratios, with associated 80% confidence intervals (CIs) and p-value.
Time frame: Day 1 to Day 28
Type of Oxygen Therapy Received Through Day 28
The analysis of this endpoint was performed on the intention-to-treat (ITT) population and only on those who received oxygen therapy. The number and percentage of patients who received different types of oxygen therapy was presented using descriptive statistics.
Time frame: Day 1 to Day 28
Duration of Hospitalization
The duration of hospitalization was performed on the intention-to-treat (ITT) population in subjects who were hospitalized. Duration of hospitalization was summarized by treatment group using descriptive statistics (N, mean, median, standard deviation, Q1, Q3, minimum, and maximum). An ANOVA model was performed to analyze the difference between treatment groups. The model included only the treatment group. Contrasts under this model allowed for the comparisons across treatment groups. The results were presented as mean treatment difference with associated 80% confidence interval (CI) and p-value.
Time frame: Day 1 through Day 28
Mortality Rate by Day 28
The analysis of this endpoint was performed on the intention-to-treat (ITT) population. The number and percentage of patients who died was presented. The percentage of patients who died was compared using a binary logistic regression. The model included only the treatment group. Contrasts under this model allowed for the comparisons across treatment groups. The results were presented as odds ratios, with associated 80% CIs and p-values.
Time frame: Day 1 to Day 28
| Milestone | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose |
|---|---|---|---|---|
| Started | 56 | 56 | 56 | 57 |
| Entered study and received at least 1 dose of study medication | 53 | 55 | 48 | 52 |
| Completed | 53 | 54 | 45 | 51 |
| Not completed | 3 | 2 | 11 | 6 |
| Withdrew: Screen failure | 0 | 0 | 6 | 2 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 4 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
Sustained clinical resolution is defined as occurring when no key COVID-19 related symptom has a score higher than 1 over a 72-hour period (as documented using an electronic patient-reported outcome \[ePRO\] instrument), except for sense of smell and taste where the score should be 0 over a 72-hour period. The time to resolution was taken as the time from randomization until the first day of the last 72-hour period where the patient met the definition of resolution within 28 days. Patients who did not meet the definition of resolution 28 days after randomization were considered not resolved. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" from the Food and Drug Administration (FDA). The symptoms are scored as on a scale of 0 to 3 for 12 of the symptoms where 0 is none and on a scale of 0 to 2 for the two other symptoms where 0 is "as usual". A higher score is a worse outcome.
| days | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose |
|---|---|---|---|---|
| Time to Sustained Clinical Resolution of Symptoms of COVID-19 (Excluding Cough, Sense of Smell and Taste) in Subjects With Confirmed, Mild to Moderate, Symptomatic COVID-19 Treatment With Dalcetrapib | 9.0 (8.0 to 14.0) | 9.0 (8.0 to 10.0) | 9.5 (8.0 to 14.0) | 10.0 (9.0 to 11.0) |
Log10 viral load, as assessed using the saliva, was summarized by treatment group using descriptive statistics (N, mean, median, standard deviation, minimum, and maximum) for each visit as well as for changes from baseline where an 80% CI were also presented. A repeated ANCOVA model was used for the data shown below, showing the mean changes from baseline to study visits (Day 3, Day 5, Day 10, and Day 28/EOS) in log10 viral load including treatment groups by study visit interaction, baseline value of log10 viral load and baseline value of log10 viral load by study visit interaction.
| log10 viral titers | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose |
|---|---|---|---|---|
| Day 3 | -0.77 (-1.04 to -0.49) | -0.79 (-1.04 to -0.54) | -0.61 (-0.89 to -0.32) | -0.79 (-1.07 to -0.51) |
| Day 5 | -1.45 (-1.72 to -1.18) | -1.50 (-1.76 to -1.25) | -1.45 (-1.73 to -1.17) | -1.27 (-1.55 to -0.99) |
| Day 10 | -3.43 (-3.79 to -3.08) | -3.24 (-3.55 to -2.92) | -3.01 (-3.38 to -2.65) | -3.23 (-3.61 to -2.85) |
| Day 28/End of Study | -5.16 (-5.40 to -4.91) | -4.96 (-5.20 to -4.72) | -5.30 (-5.57 to -5.03) | -5.16 (-5.42 to -4.90) |
Log10 viral load, as assessed using the nasal swab, was summarized by treatment group using descriptive statistics (N, mean, median, standard deviation, minimum, and maximum) for each visit as well as for changes from baseline where an 80% CI were also presented. A repeated ANCOVA model was used for the data shown below, showing the mean changes from baseline to study visits (Day 3, Day 5, Day 10, and Day 28/EOS) in log10 viral load including treatment groups by study visit interaction, baseline value of log10 viral load and baseline value of log10 viral load by study visit interaction.
| log10 viral titers | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose |
|---|---|---|---|---|
| Day 3 | -0.94 (-1.18 to -0.71) | -1.17 (-1.39 to -0.94) | -0.84 (-1.09 to -0.60) | -0.92 (-1.17 to -0.68) |
| Day 5 | -1.87 (-2.15 to -1.60) | -2.25 (-2.53 to -1.98) | -1.47 (-1.76 to -1.17) | -2.00 (-2.29 to -1.71) |
| Day 10 | -4.76 (-5.08 to -4.45) | -4.42 (-4.72 to -4.11) | -3.87 (-4.22 to -3.52) | -4.23 (-4.59 to -3.87) |
| Day 28/End of Study | -6.24 (-6.32 to -6.15) | -6.29 (-6.38 to -6.21) | -6.26 (-6.36 to -6.17) | -6.34 (-6.43 to -6.25) |
Sustained clinical resolution is defined as occurring when no key COVID-19 related symptom has a score higher than 1 over a 72-hour period (as documented using an electronic patient-reported outcome \[ePRO\] instrument). The time to resolution was taken as the time from randomization until the first day of the last 72-hour period where the patient met the definition of resolution within 28 days. Patients who did not meet the definition of resolution 28 days after randomization were considered not resolved. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" from the Food and Drug Administration (FDA). The symptoms are scored as on a scale of 0 to 3 for 12 of the symptoms where 0 is none and on a scale of 0 to 2 for the two other symptoms where 0 is "as usual". A higher score is a worse outcome.
| days | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose |
|---|---|---|---|---|
| Time to Sustained Complete Clinical Resolution of Symptoms in Subjects With Confirmed, Mild to Moderate, Symptomatic COVID-19 Treatment With Dalcetrapib | 28.0 (16.0 to 28.0) | 28.0 (15.0 to 28.0) | 28.0 (28.0 to 29.0) | 28.0 (28.0 to 28.0) |
Viral clearance based on polymerase chain reaction (PCR) test for Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) using nasal swab and saliva samples was performed on the intention-to-treat (ITT) population. Viral clearance was summarized by treatment group using Kaplan-Meier methods. Median and associated 80% confidence interval (CI) was presented. The number and percentage of patients who did not show viral clearance, did show viral clearance, and patients censored were presented.
| Participants | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose |
|---|---|---|---|---|
| Viral Clearance (saliva) — Yes | 12 | 10 | 9 | 14 |
| Viral Clearance (saliva) — No | 41 | 44 | 39 | 36 |
| Viral Clearance (nasal swab) — Yes | 25 | 22 | 12 | 14 |
| Viral Clearance (nasal swab) — No | 28 | 32 | 36 | 36 |
Complete clinical resolution is defined as occurring when no key COVID-19 related symptom (excluding cough, sense of smell and taste) has a score higher than 0 over a 72-hour period. The time to resolution was taken as the time from randomization until the first day of the last 72 hour period where the patient met the definition of resolution within 28 days. Patients who did not meet the definition of resolution 28 days after randomization were considered not resolved. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" was used. The symptoms are scored as on a scale of 0 to 3 for 12 of the symptoms where 0 is none and on a scale of 0 to 2 for the two other symptoms where 0 is "as usual". A higher score is a worse outcome.
| days | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose |
|---|---|---|---|---|
| Time to Complete Clinical Resolution (Excluding Cough, Sense of Smell and Taste) Defined in the Same Way as the Primary Endpoint, But Considering That All Symptoms Must Resolve to a Score of 0 for 72 Hours | 28.0 (28.0 to 29.0) | 28.0 (28.0 to 28.0) | 28.0 (28.0 to 29.0) | 28.0 (28.0 to 29.0) |
Sustained clinical resolution is defined as occurring when no key COVID-19 related symptom has a score higher than 0 over a 72-hour period. The time to resolution was taken as the time from randomization until the first day of the last 72 hour period where the patient met the definition of resolution within 28 days. Patients who did not meet the definition of resolution 28 days after randomization were considered not resolved. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" was used. The symptoms are scored as on a scale of 0 to 3 for 12 of the symptoms where 0 is none and on a scale of 0 to 2 for the two other symptoms where 0 is "as usual". A higher score is a worse outcome. Resolution must have occurred within 28 days. Time of resolution of 29 days was imputed in censored subjects.
| days | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose |
|---|---|---|---|---|
| Time to Complete Clinical Resolution | 29.0 (28.0 to 29.0) | 28.0 (28.0 to 29.0) | 29.0 (28.0 to 29.0) | 28.5 (28.0 to 29.0) |
COVID-19 total symptom severity score was summarized by treatment group using descriptive statistics (N, mean, median, standard deviation, minimum, and maximum) for each visit as well as for changes from baseline where an 80% confidence interval (CI) was also presented. Mean changes from baseline were analyzed using a repeated measures ANCOVA model. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" from the Food and Drug Administration (FDA) document "Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment Guidance for Industry". Symptoms are scored as on a scale of 0 to 3 for 12 the symptoms and on a scale of 0 to 2 for two symptoms. The sum of all 14 symptom scores is reported, where 0 is the minimum and 40 is the maximum. A higher score is a worse outcome.
| score on a scale | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose |
|---|---|---|---|---|
| Baseline | 10.70 ± 4.98 | 11.11 ± 4.34 | 10.88 ± 4.63 | 9.02 ± 3.92 |
| Day 2 | 10.30 ± 5.35 | 10.76 ± 4.58 | 11.55 ± 4.29 | 11.39 ± 5.06 |
| Change from baseline to Day 2 | -0.40 ± 3.85 | -0.39 ± 3.52 | 0.68 ± 3.65 | 2.35 ± 3.90 |
| Day 3 | 8.85 ± 4.79 | 9.42 ± 4.53 | 10.57 ± 5.04 | 10.12 ± 5.40 |
| Change from baseline to Day 3 | -1.85 ± 3.78 | -1.69 ± 3.80 | -0.38 ± 4.46 | 1.08 ± 4.71 |
| Day 4 | 8.24 ± 5.13 | 9.60 ± 5.09 | 10.75 ± 5.87 | 9.34 ± 5.39 |
| Change from baseline to Day 4 | -2.54 ± 5.04 | -1.55 ± 4.73 | -0.13 ± 5.27 | 0.23 ± 5.03 |
| Day 5 | 7.90 ± 4.97 | 8.89 ± 5.56 | 9.29 ± 4.78 | 8.36 ± 4.50 |
| Change from baseline to Day 5 | -2.79 ± 4.64 | -2.26 ± 4.98 | -1.58 ± 6.03 | -0.56 ± 4.47 |
| Day 6 | 6.98 ± 5.09 | 7.94 ± 5.44 | 8.09 ± 4.86 | 8.24 ± 6.23 |
| Change from baseline to Day 6 | -3.67 ± 5.57 | -3.23 ± 5.32 | -2.44 ± 5.56 | -0.71 ± 5.61 |
| Day 7 | 6.0 ± 5.5 | 5.75 ± 3.94 | 8.39 ± 6.49 | 6.91 ± 4.57 |
| Change from baseline to Day 7 | -4.65 ± 5.77 | -5.29 ± 4.85 | -2.24 ± 7.20 | -2.02 ± 4.58 |
| Day 8 | 5.06 ± 4.14 | 5.82 ± 4.13 | 7.02 ± 6.25 | 5.50 ± 4.03 |
| Change from baseline to Day 8 | -5.48 ± 5.34 | -5.38 ± 4.76 | -3.64 ± 6.88 | -3.48 ± 4.18 |
| Day 9 | 4.44 ± 3.76 | 5.22 ± 4.34 | 6.86 ± 6.45 | 4.90 ± 2.80 |
| Change from baseline to Day 9 | -6.10 ± 5.88 | -6.20 ± 4.75 | -4.00 ± 7.58 | -3.95 ± 4.39 |
| Day 10 | 3.90 ± 3.62 | 4.37 ± 3.79 | 5.85 ± 6.67 | 4.00 ± 2.96 |
| Change from baseline to Day 10 | -6.67 ± 5.41 | -6.96 ± 4.25 | -4.59 ± 7.56 | -4.77 ± 4.36 |
| Follow-up visit 1 (Day 14) | 3.22 ± 3.72 | 3.39 ± 3.23 | 4.23 ± 6.19 | 3.40 ± 3.58 |
| Change from baseline to follow-up visit 1 | -7.42 ± 5.74 | -7.90 ± 4.35 | -6.59 ± 7.24 | 5.21 ± 4.95 |
| Follow-up visit 2 (Day 28/End of Study) | 1.84 ± 2.49 | 2.23 ± 2.85 | 2.89 ± 6.20 | 1.75 ± 2.05 |
| Change from baseline to follow-up visit 2 | -8.96 ± 5.14 | -9.02 ± 4.26 | -7.78 ± 7.12 | -7.17 ± 4.74 |
The number and percentage of patients for each WHO clinical outcome score was summarized. Scores were compared using the Mann-Whitney-Wilcoxon test. This scale is called the "WHO Clinical Outcome Scale". It is scored from 0 to 9 where 9 is the most severe disease presentation. A higher score is a worse outcome.
| Participants | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose |
|---|---|---|---|---|
| Screening — WHO Clinical Outcome Scale Score 0 | 0 | 0 | 0 | 0 |
| Screening — WHO Clinical Outcome Scale Score 1 | 18 | 15 | 19 | 23 |
| Screening — WHO Clinical Outcome Scale Score 2 | 35 | 40 | 29 | 29 |
| Screening — WHO Clinical Outcome Scale Score 3 | 0 | 0 | 0 | 0 |
| Screening — WHO Clinical Outcome Scale Score 4 | 0 | 0 | 0 | 0 |
| Screening — WHO Clinical Outcome Scale Score 5 | 0 | 0 | 0 | 0 |
| Screening — WHO Clinical Outcome Scale Score 6 | 0 | 0 | 0 | 0 |
| Screening — WHO Clinical Outcome Scale Score 7 | 0 | 0 | 0 | 0 |
| Screening — WHO Clinical Outcome Scale Score 8 | 0 | 0 | 0 | 0 |
| Day 1 — WHO Clinical Outcome Scale Score 0 | 0 | 0 | 0 | 0 |
| Day 1 — WHO Clinical Outcome Scale Score 1 | 15 | 13 | 17 | 18 |
| Day 1 — WHO Clinical Outcome Scale Score 2 | 38 | 42 | 31 | 34 |
| Day 1 — WHO Clinical Outcome Scale Score 3 | 0 | 0 | 0 | 0 |
| Day 1 — WHO Clinical Outcome Scale Score 4 | 0 | 0 | 0 | 0 |
| Day 1 — WHO Clinical Outcome Scale Score 5 | 0 | 0 | 0 | 0 |
| Day 1 — WHO Clinical Outcome Scale Score 6 | 0 | 0 | 0 | 0 |
| Day 1 — WHO Clinical Outcome Scale Score 7 | 0 | 0 | 0 | 0 |
| Day 1 — WHO Clinical Outcome Scale Score 8 | 0 | 0 | 0 | 0 |
| Day 3 — WHO Clinical Outcome Scale Score 0 | 0 | 0 | 0 | 0 |
| Day 3 — WHO Clinical Outcome Scale Score 1 | 18 | 16 | 15 | 19 |
| Day 3 — WHO Clinical Outcome Scale Score 2 | 35 | 38 | 32 | 25 |
| Day 3 — WHO Clinical Outcome Scale Score 3 | 0 | 0 | 0 | 0 |
| Day 3 — WHO Clinical Outcome Scale Score 4 | 0 | 0 | 0 | 0 |
| Day 3 — WHO Clinical Outcome Scale Score 5 | 0 | 0 | 0 | 0 |
| Day 3 — WHO Clinical Outcome Scale Score 6 | 0 | 0 | 0 | 0 |
| Day 3 — WHO Clinical Outcome Scale Score 7 | 0 | 0 | 0 | 0 |
| Day 3 — WHO Clinical Outcome Scale Score 8 | 0 | 0 | 0 | 0 |
| Day 5 — WHO Clinical Outcome Scale Score 0 | 0 | 0 | 1 | 0 |
| Day 5 — WHO Clinical Outcome Scale Score 1 | 17 | 21 | 12 | 19 |
| Day 5 — WHO Clinical Outcome Scale Score 2 | 34 | 31 | 29 | 27 |
| Day 5 — WHO Clinical Outcome Scale Score 3 | 0 | 0 | 0 | 0 |
| Day 5 — WHO Clinical Outcome Scale Score 4 | 0 | 1 | 0 | 0 |
| Day 5 — WHO Clinical Outcome Scale Score 5 | 0 | 0 | 0 | 0 |
| Day 5 — WHO Clinical Outcome Scale Score 6 | 0 | 0 | 0 | 0 |
| Day 5 — WHO Clinical Outcome Scale Score 7 | 0 | 0 | 0 | 0 |
| Day 5 — WHO Clinical Outcome Scale Score 8 | 0 | 0 | 0 | 0 |
| End of Treatment (Day 10) — WHO Clinical Outcome Scale Score 0 | 3 | 5 | 5 | 1 |
| End of Treatment (Day 10) — WHO Clinical Outcome Scale Score 1 | 29 | 27 | 19 | 18 |
| End of Treatment (Day 10) — WHO Clinical Outcome Scale Score 2 | 19 | 20 | 22 | 31 |
| End of Treatment (Day 10) — WHO Clinical Outcome Scale Score 3 | 1 | 0 | 1 | 0 |
| End of Treatment (Day 10) — WHO Clinical Outcome Scale Score 4 | 0 | 2 | 0 | 0 |
| End of Treatment (Day 10) — WHO Clinical Outcome Scale Score 5 | 0 | 0 | 0 | 0 |
| End of Treatment (Day 10) — WHO Clinical Outcome Scale Score 6 | 0 | 0 | 0 | 0 |
| End of Treatment (Day 10) — WHO Clinical Outcome Scale Score 7 | 0 | 0 | 0 | 0 |
| End of Treatment (Day 10) — WHO Clinical Outcome Scale Score 8 | 0 | 0 | 0 | 0 |
| Follow-up visit 1 (Day 14) — WHO Clinical Outcome Scale Score 0 | 10 | 14 | 12 | 13 |
| Follow-up visit 1 (Day 14) — WHO Clinical Outcome Scale Score 1 | 31 | 21 | 23 | 24 |
| Follow-up visit 1 (Day 14) — WHO Clinical Outcome Scale Score 2 | 11 | 18 | 8 | 11 |
| Follow-up visit 1 (Day 14) — WHO Clinical Outcome Scale Score 3 | 0 | 1 | 0 | 0 |
| Follow-up visit 1 (Day 14) — WHO Clinical Outcome Scale Score 4 | 0 | 0 | 0 | 0 |
| Follow-up visit 1 (Day 14) — WHO Clinical Outcome Scale Score 5 | 0 | 0 | 0 | 0 |
| Follow-up visit 1 (Day 14) — WHO Clinical Outcome Scale Score 6 | 0 | 0 | 0 | 0 |
| Follow-up visit 1 (Day 14) — WHO Clinical Outcome Scale Score 7 | 0 | 0 | 1 | 0 |
| Follow-up visit 1 (Day 14) — WHO Clinical Outcome Scale Score 8 | 0 | 0 | 0 | 0 |
| Follow-up visit 2 (Day 28/End Of Study) — WHO Clinical Outcome Scale Score 0 | 28 | 21 | 19 | 19 |
| Follow-up visit 2 (Day 28/End Of Study) — WHO Clinical Outcome Scale Score 1 | 20 | 21 | 21 | 24 |
| Follow-up visit 2 (Day 28/End Of Study) — WHO Clinical Outcome Scale Score 2 | 5 | 12 | 5 | 8 |
| Follow-up visit 2 (Day 28/End Of Study) — WHO Clinical Outcome Scale Score 3 | 0 | 0 | 0 | 0 |
| Follow-up visit 2 (Day 28/End Of Study) — WHO Clinical Outcome Scale Score 4 | 0 | 0 | 0 | 0 |
| Follow-up visit 2 (Day 28/End Of Study) — WHO Clinical Outcome Scale Score 5 | 0 | 0 | 0 | 0 |
| Follow-up visit 2 (Day 28/End Of Study) — WHO Clinical Outcome Scale Score 6 | 0 | 0 | 0 | 0 |
| Follow-up visit 2 (Day 28/End Of Study) — WHO Clinical Outcome Scale Score 7 | 0 | 0 | 0 | 0 |
| Follow-up visit 2 (Day 28/End Of Study) — WHO Clinical Outcome Scale Score 8 | 0 | 0 | 1 | 0 |
The analysis of this endpoint was performed on the intention-to-treat (ITT) population. The percentage of patients who were hospitalized was compared using a binary logistic regression analysis. The model included only the treatment group. The results were presented as odds ratios, with associated 80% CIs and p-value.
| Participants | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose |
|---|---|---|---|---|
| Yes, hospitalized | 2 | 4 | 3 | 1 |
| No, not hospitalized | 51 | 51 | 45 | 51 |
The analysis of this endpoint was performed on the intention-to-treat (ITT) population. The number and percentage of patients who progressed to oxygen therapy was presented. The percentage of patients who had progressed to oxygen therapy was compared using a binary logistic regression analysis. The model included only the treatment group. The results were presented as odds ratios, with associated 80% confidence intervals (CIs) and p-value.
| Participants | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose |
|---|---|---|---|---|
| Yes, progressed to oxygen therapy | 1 | 4 | 2 | 1 |
| No, did not progress to oxygen therapy | 52 | 51 | 46 | 51 |
The analysis of this endpoint was performed on the intention-to-treat (ITT) population and only on those who received oxygen therapy. The number and percentage of patients who received different types of oxygen therapy was presented using descriptive statistics.
| Participants | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose |
|---|---|---|---|---|
| Supplemental oxygen | 1 | 4 | 1 | 1 |
| Mechanical ventilation | 0 | 0 | 1 | 0 |
The duration of hospitalization was performed on the intention-to-treat (ITT) population in subjects who were hospitalized. Duration of hospitalization was summarized by treatment group using descriptive statistics (N, mean, median, standard deviation, Q1, Q3, minimum, and maximum). An ANOVA model was performed to analyze the difference between treatment groups. The model included only the treatment group. Contrasts under this model allowed for the comparisons across treatment groups. The results were presented as mean treatment difference with associated 80% confidence interval (CI) and p-value.
| days | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose |
|---|---|---|---|---|
| Duration of Hospitalization | 3.0 ± 0.0 | 5.75 ± 5.19 | 8.67 ± 12.42 | 3.0 ± 0 |
The analysis of this endpoint was performed on the intention-to-treat (ITT) population. The number and percentage of patients who died was presented. The percentage of patients who died was compared using a binary logistic regression. The model included only the treatment group. Contrasts under this model allowed for the comparisons across treatment groups. The results were presented as odds ratios, with associated 80% CIs and p-values.
| Participants | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose |
|---|---|---|---|---|
| No, did not die | 53 | 55 | 47 | 52 |
| Yes, died | 0 | 0 | 1 | 0 |
Collected over Adverse event (AE) data were collected for approximately 1 month. All subjects were closely monitored for adverse events from informed consent for at least 18 days after the final dose of study treatment (until Day 28 ±2). Subjects who withdrew early from the study had follow-up phone calls to collect safety data until End of Study on Day 28±2.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Tablets | 0/53 (0%) | 2/53 (3.8%) | 29/53 (54.7%) |
| 900 mg Dose | 0/55 (0%) | 4/55 (7.3%) | 27/55 (49.1%) |
| 1800 mg Dose | 1/48 (2.1%) | 4/48 (8.3%) | 33/48 (68.8%) |
| 3600 mg Dose | 0/52 (0%) | 1/52 (1.9%) | 46/52 (88.5%) |
| Event | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose |
|---|---|---|---|---|
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 2/53 | 3/55 | 1/48 | 0/52 |
| PneumoniaInfections and infestations | 0/53 | 2/55 | 0/48 | 1/52 |
| Proctitis ulcerativeGastrointestinal disorders | 0/53 | 0/55 | 1/48 | 0/52 |
| AstheniaGeneral disorders | 0/53 | 0/55 | 1/48 | 0/52 |
| Rash maculopapularRespiratory, thoracic and mediastinal disorders | 0/53 | 0/55 | 1/48 | 1/52 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/53 | 1/55 | 0/48 | 0/52 |
| Deep vein thrombosisVascular disorders | 0/53 | 1/55 | 0/48 | 0/52 |
| Event | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose |
|---|---|---|---|---|
| DiarrheaGastrointestinal disorders | 10/53 | 14/55 | 14/48 | 30/52 |
| Gastrointestinal disorderGastrointestinal disorders | 5/53 | 6/55 | 6/48 | 12/52 |
| Laboratory test abnormalInvestigations | 7/53 | 5/55 | 5/48 | 4/52 |
| RashSkin and subcutaneous tissue disorders | 3/53 | 4/55 | 5/48 | 3/52 |
| Feces softGastrointestinal disorders | 2/53 | 1/55 | 4/48 | 2/52 |
| Gastric disorderGastrointestinal disorders | 0/53 | 0/55 | 4/48 | 1/52 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 2/53 | 4/55 | 2/48 | 0/52 |
| NauseaGastrointestinal disorders | 2/53 | 2/55 | 3/48 | 1/52 |
Of the 225 randomized subjects, a total of 208 subjects received at least one dose of study medication, for which baseline data are presented here. The overall number of baseline participants in each arm reflects the number of subjects who took at least one dose of study medication in each arm, not the total number randomized in each arm.
| Age, Continuous(years) | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose | Total |
|---|---|---|---|---|---|
| Mean | 43.9 ± 13.2 | 46.7 ± 10.4 | 42.5 ± 12.0 | 46.5 ± 11.0 | 44.9 ± 11.9 |
| Sex: Female, Male(Participants) | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose | Total |
|---|---|---|---|---|---|
| Female | 34 | 34 | 19 | 28 | 115 |
| Male | 19 | 21 | 29 | 24 | 93 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 2 | 1 | 7 |
| Not Hispanic or Latino | 51 | 53 | 46 | 50 | 200 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 3 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 1 | 2 |
| White | 53 | 53 | 45 | 51 | 202 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose | Total |
|---|---|---|---|---|---|
| Canada | 53 | 55 | 48 | 52 | 208 |
| Smoking status(Participants) | Placebo Tablets | 900 mg Dose | 1800 mg Dose | 3600 mg Dose | Total |
|---|---|---|---|---|---|
| Never smoker | 28 | 33 | 29 | 25 | 115 |
| Current smoker | 8 | 4 | 7 | 6 | 25 |
| Former smoker | 17 | 18 | 12 | 21 | 68 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2021 to primary completion in May 2021, 4 months.
Results were first posted in Dec 2022, 1 year 6 months after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 4 months is below that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dalcetrapib